routes of administration

Alternative Routes to
Intravenous TXA Administration

Intravenous (IV) Tranexamic Acid (TXA) reduces death from bleeding in patients with postpartum haemorrhage (PPH) and traumatic injuries.  

However, patients must be treated urgently – most haemorrhage deaths occur within hours of bleeding onset, and treatment delay reduces the survival benefit from TXA. With every 15 minute delay, 10% of the survival benefit is lost. 

One of the main obstacles to reducing treatment delay is the need for an IV injection. 

In trauma patients, securing IV access at the injury scene can be difficult, particularly in trapped patients.

In countries with limited pre-hospital care, most trauma patients arrive at hospital too late to benefit from TXA. 

The WOMAN trial showed that IV administration of TXreduces PPH deaths by one-third, TXA was incorporated into the World Health Organisation guidelines. 

To ensure equitable access to this life-saving treatment, finding other routes to give TXA became a WHO priority.  

Because many women die soon after PPH onset and the life-saving effect of TXA decreases by 10% with every 15-minute delay, finding alternatives to IV administration offers women effective emergency care wherever they give birth. 

Click HERE to watch a PPH stakeholder webinar discussing alternative routes for the administration of tranexamic acid (TXA) in post-partum haemorrhage (PPH).

Learn About Different Routes of Administration

Routes Of

Stakeholder webinar: Alternative routes for the administration of tranexamic acid (TXA) in post-partum haemorrhage (PPH)

Discover More About TXA